Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Operating Expenses came in at $7.0 million in Q4 2025, up 2454.32% YoY from $275613.0 in Q4 2024, and up 281.73% on a QoQ basis from $1.8 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Operating Expenses data on file, last reported at $7.0 million in Q4 2025.
- Quarterly Operating Expenses rose 2454.32% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.9 million (up 834.25% YoY) and the FY2025 annual result came in at $11.9 million, up 834.25% from the prior year.
- Operating Expenses grew to $7.0 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $7.0 million in Q4 2025 to a low of $271726.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.12 Mn | 7.12 Mn | - | 6.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.04 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 364,368.00 |
| Dec 31, 2024 | 275,613.00 |
| Sep 30, 2024 | 299,999.00 |
| Jun 30, 2024 | 427,757.00 |
| Mar 31, 2024 | 271,726.00 |